201 related articles for article (PubMed ID: 29052441)
1. Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes.
Scheen AJ; Paquot N; Lefèbvre PJ
Expert Opin Investig Drugs; 2017 Dec; 26(12):1373-1389. PubMed ID: 29052441
[TBL] [Abstract][Full Text] [Related]
2. Glucagon as a target for the treatment of Type 2 diabetes.
Sloop KW; Michael MD; Moyers JS
Expert Opin Ther Targets; 2005 Jun; 9(3):593-600. PubMed ID: 15948676
[TBL] [Abstract][Full Text] [Related]
3. A survey of small molecule glucagon receptor antagonists from recent patents (2006 - 2010).
Shen DM; Lin S; Parmee ER
Expert Opin Ther Pat; 2011 Aug; 21(8):1211-40. PubMed ID: 21635155
[TBL] [Abstract][Full Text] [Related]
4. Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).
Filipski KJ
Expert Opin Ther Pat; 2015 Jul; 25(7):819-30. PubMed ID: 25828189
[TBL] [Abstract][Full Text] [Related]
5. Hypoglycemic Effect of Combined Ghrelin and Glucagon Receptor Blockade.
Mani BK; Uchida A; Lee Y; Osborne-Lawrence S; Charron MJ; Unger RH; Berglund ED; Zigman JM
Diabetes; 2017 Jul; 66(7):1847-1857. PubMed ID: 28487437
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice.
Omar BA; Andersen B; Hald J; Raun K; Nishimura E; Ahrén B
Diabetes; 2014 Jan; 63(1):101-10. PubMed ID: 24062250
[TBL] [Abstract][Full Text] [Related]
7. Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes.
Lang S; Yang J; Yang K; Gu L; Cui X; Wei T; Liu J; Le Y; Wang H; Wei R; Hong T
BMJ Open Diabetes Res Care; 2020 Mar; 8(1):. PubMed ID: 32139602
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice.
Gu W; Lloyd DJ; Chinookswong N; Komorowski R; Sivits G; Graham M; Winters KA; Yan H; Boros LG; Lindberg RA; Véniant MM
J Pharmacol Exp Ther; 2011 Jul; 338(1):70-81. PubMed ID: 21471191
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic modeling of a monoclonal antibody antagonist of glucagon receptor in male ob/ob mice.
Lau YY; Ma P; Gibiansky L; Komorowski R; Wang J; Wang G; Yan H; Véniant MM; Kakkar T
AAPS J; 2009 Dec; 11(4):700-9. PubMed ID: 19851873
[TBL] [Abstract][Full Text] [Related]
10. Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor.
Gu W; Winters KA; Motani AS; Komorowski R; Zhang Y; Liu Q; Wu X; Rulifson IC; Sivits G; Graham M; Yan H; Wang P; Moore S; Meng T; Lindberg RA; Véniant MM
Am J Physiol Endocrinol Metab; 2010 Oct; 299(4):E624-32. PubMed ID: 20647556
[TBL] [Abstract][Full Text] [Related]
11. Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes.
Eriksson O; Haack T; Hijazi Y; Teichert L; Tavernier V; Laitinen I; Berglund JE; Antoni G; Velikyan I; Johansson L; Pierrou S; Wagner M; Tillner J
Sci Rep; 2020 Oct; 10(1):16758. PubMed ID: 33028880
[TBL] [Abstract][Full Text] [Related]
12. Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors).
Nunez DJ; D'Alessio D
Diabetes Obes Metab; 2018 Feb; 20(2):233-237. PubMed ID: 28842950
[No Abstract] [Full Text] [Related]
13. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia.
Gu W; Yan H; Winters KA; Komorowski R; Vonderfecht S; Atangan L; Sivits G; Hill D; Yang J; Bi V; Shen Y; Hu S; Boone T; Lindberg RA; Véniant MM
J Pharmacol Exp Ther; 2009 Dec; 331(3):871-81. PubMed ID: 19720878
[TBL] [Abstract][Full Text] [Related]
14. Recent progress in the development of small-molecule glucagon receptor antagonists.
Sammons MF; Lee EC
Bioorg Med Chem Lett; 2015 Oct; 25(19):4057-64. PubMed ID: 26271588
[TBL] [Abstract][Full Text] [Related]
15. Computational identification of novel natural inhibitors of glucagon receptor for checking type II diabetes mellitus.
Grover S; Dhanjal JK; Goyal S; Grover A; Sundar D
BMC Bioinformatics; 2014; 15 Suppl 16(Suppl 16):S13. PubMed ID: 25521597
[TBL] [Abstract][Full Text] [Related]
16. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
17. Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys.
Okamoto H; Kim J; Aglione J; Lee J; Cavino K; Na E; Rafique A; Kim JH; Harp J; Valenzuela DM; Yancopoulos GD; Murphy AJ; Gromada J
Endocrinology; 2015 Aug; 156(8):2781-94. PubMed ID: 26020795
[TBL] [Abstract][Full Text] [Related]
18. Absence of glucagon and insulin action reveals a role for the GLP-1 receptor in endogenous glucose production.
Jun LS; Millican RL; Hawkins ED; Konkol DL; Showalter AD; Christe ME; Michael MD; Sloop KW
Diabetes; 2015 Mar; 64(3):819-27. PubMed ID: 25288673
[TBL] [Abstract][Full Text] [Related]
19. First proof of pharmacology in humans of a novel glucagon receptor antisense drug.
van Dongen MG; Geerts BF; Morgan ES; Brandt TA; de Kam ML; Romijn JA; Cohen AF; Bhanot S; Burggraaf J
J Clin Pharmacol; 2015 Mar; 55(3):298-306. PubMed ID: 25197025
[TBL] [Abstract][Full Text] [Related]
20. Glucagon receptor is required for long-term survival: a natural history study of the Mahvash disease in a murine model.
Yu R; Ren SG; Mirocha J
Endocrinol Nutr; 2012 Nov; 59(9):523-30. PubMed ID: 22951296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
